Ipersart (Losartan Potassium, Hydrochlorothiazide)

Losartan potassium selectively blocks the angiotensin II type 1 (AT1) receptors on blood vessels and adrenal tissue. By preventing angiotensin II from binding, it reduces vasoconstriction, aldosterone secretion, and sympathetic activation, leading to relaxed blood vessels and lower arterial pressure.

The dosage of Ipersart is individualized by the prescribing clinician based on the patient’s blood‑pressure readings, renal function, and response to therapy. The prescriber determines the appropriate strength and frequency, and patients should follow the exact instructions on the prescription label.

Ipersart is classified as pregnancy Category D, indicating evidence of fetal risk, and it should not be used by pregnant women. It is also not recommended while breastfeeding because the active ingredients can pass into breast milk and may affect the infant. Alternative therapies should be considered in these situations.

To request Ipersart, visit the product page on gnhindia.com, enter the desired quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any required import documentation.

Ipersart combines an ARB with a thiazide diuretic, offering dual mechanisms in a single tablet. Compared with monotherapy agents such as a single ARB or a diuretic alone, the combination can achieve greater blood‑pressure reduction and may simplify treatment regimens, but it also carries the combined side‑effect profile of both drug classes.

Ipersart tablets should be stored at room temperature, preferably below 25 °C, in their original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use it after the expiration date printed on the label.

Ipersart is taken orally, usually once daily, with or without food, as directed by the prescriber. The tablet should be swallowed whole with a full glass of water and not crushed or chewed unless specifically instructed by a healthcare professional.

The most serious adverse events include severe hypotension, acute kidney injury, and hyperkalemia, especially when used with other medications that affect renal function or potassium balance. Patients should be monitored for signs of dizziness, rapid weight loss, muscle weakness, or abnormal laboratory values, and medical attention should be sought promptly if these occur.

Ipersart should be avoided in individuals with known hypersensitivity to losartan, hydrochlorothiazide, or any component of the formulation. It is also contraindicated in patients with severe renal impairment, severe liver disease, or those who are pregnant. Clinicians must assess each patient’s medical history before initiating therapy.